<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006898</url>
  </required_header>
  <id_info>
    <org_study_id>PBOPC01</org_study_id>
    <nct_id>NCT05006898</nct_id>
  </id_info>
  <brief_title>Compound to Control Presbyopia Symptoms</brief_title>
  <official_title>Synergistic Use of Pilocarpine-Brimonidine-Oxymetazoline to Control Presbyopia Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optall Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optall Vision</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low dose compose to control presbyopia symptoms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A los dose compound including pilocarpine, brimonidine and oxymetazoline was use to control&#xD;
      presbyopia symptoms compared to pilocarpine and brimonidine in low doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilocarpine, brimonidine, oxymetazoline (PBO) compound was instilled in the non-dominant eye of presbyopic patients, while in the dominant eye pilocarpine or brimonidine were instilled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>While in office the care provider took a number out of a closed container. Number 1 was designated for the placebo; Number 2 was designated for the compound</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Jaeger notation near uncorrected visual acuity change</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of lines improved 1 hour after drug instillation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of PBO compound Jaeger notation improvement vs Pilocarpine or Brimonidine alone</measure>
    <time_frame>1 hour</time_frame>
    <description>Number of lines improve comparing PBO compound vs Pilocarpine or Brimonidine</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>PBO Investigational drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilocarpine, brimonidine, oxymetazoline combined with hyaluronic acid and bromfenac combined in an ophthalmic solution to be randomly instilled in one eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pilocarpine was instilled in the other oye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine was instilled in the other eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PBO to control presbyopia symptoms</intervention_name>
    <description>Low dose PBO to control presbyopia symptoms</description>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_label>PBO Investigational drug</arm_group_label>
    <arm_group_label>Pilocarpine</arm_group_label>
    <other_name>Pilocarpine</other_name>
    <other_name>Brimonidine</other_name>
    <other_name>Oxymetazoline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy&#xD;
&#xD;
          -  Presbyopic&#xD;
&#xD;
          -  40 - 59 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetics&#xD;
&#xD;
          -  Previous eye surgery&#xD;
&#xD;
          -  Previous eye disease&#xD;
&#xD;
          -  &gt; 0.50 myopia&#xD;
&#xD;
          -  &gt; 1.5 hyperopia or astigmatism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesar Alejandro S Galeana</last_name>
    <role>Principal Investigator</role>
    <affiliation>Optall Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optall Vision</name>
      <address>
        <city>Mexico City</city>
        <zip>01090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Optall Vision</investigator_affiliation>
    <investigator_full_name>Cesar Alejandro Sanchez Galeana</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

